Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Iloprost

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    48 result(s) found for: Iloprost. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2006-000905-41 Sponsor Protocol Number: none Start Date*: 2006-06-07
    Sponsor Name:ao. Univ. Prof. Dr. Elisabeth Aberer
    Full Title: Offene, monozentrische, randomisierte, placebo-kontrollierte, einfach blinde und Observer-blinde klinische Studie bei PatientInnen mit Raynaud Syndrom mit / ohne progressiver systemischer Skleroder...
    Medical condition: Raynaud syndrome with / without systemic sclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001551-11 Sponsor Protocol Number: Iloprost Start Date*: 2004-09-22
    Sponsor Name:Lund University Hospital
    Full Title: Behandling av förhöjt pulmonellt arteriellt tryck med inhalerad iloprost
    Medical condition: Nyfödda barn som är i behov av respiratorvård pga RDS, mekoniumaspiration eller primär lunghypertension
    Disease:
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-010703-80 Sponsor Protocol Number: AC-063A301 Start Date*: 2009-06-11
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients with Symptomatic Pulmonary ...
    Medical condition: Indication: Symptomatic Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064911 Pulmonary arterial hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002783-12 Sponsor Protocol Number: BAYq6256/16483 Start Date*: 2014-01-07
    Sponsor Name:Bayer HealthCare AG
    Full Title: A multi-center, open-label, randomized cross-over study to compare the acute tolerability and pharmacokinetics of BAY Q 6256 (iloprost; Ventavis) inhalation using the I-Neb nebulizer and the FOX ne...
    Medical condition: Patients with Pulmonary arterial hypertension, WHO class III, who have been on therpay with Ventavis 10 for at least 4 weeks
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10036727 Primary pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004567-80 Sponsor Protocol Number: ILOFLOW1.0 Start Date*: 2012-06-05
    Sponsor Name:Georg Hagmüller Institute for Vascular Research
    Full Title: The intraoperative arterial measurement of the blood flow after Iloproststimulation in diabetics and non-diabetics: Implication for Outcome - prediction and perioperative therapy.
    Medical condition: We think that the blood flow increases during intraarterial injection of iloprost during surgical treatment in distal vessels in patients with arteriosclerosis and diabetes and non diabetes in the ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002090-12 Sponsor Protocol Number: Ilocard Start Date*: 2009-03-04
    Sponsor Name:Hospital of the university of munich
    Full Title: Effect of Iloprost inhalation before and during extracorporeal circulation (ECC) on perioperative morbidity and outcome in high risk cardiac surgical patients
    Medical condition: In this study effects of the intra operative, prophylactic inhalation of Iloprost (Ventavis) before and during extracorporal circulation on perioperative morbidity and outcome in high risk cardiac ...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10036727 Primary pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-006192-13 Sponsor Protocol Number: C200-006 Start Date*: 2006-06-22
    Sponsor Name:Actelion Pharmaceuticals US, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE ADDITION OF INHALED ILOPROST IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) RECEIVING ORAL SI...
    Medical condition: Pulmonary Arterial Hypertension (PAH) is a condition that is characterized by increased pulmonary arterial pressure and vascular resistance that can lead to right ventricular failure and death.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10037400 Pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Prematurely Ended) AT (Prematurely Ended) ES (Completed) PT (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-011013-24 Sponsor Protocol Number: AC-063A302 Start Date*: 2009-06-03
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: A Multicenter, Double-blind, Randomized Study comparing the Safety and Tolerability of Iloprost inhalation solution delivered by I-neb utilizing Power disc-15 and Power disc-6 in Patients with Symp...
    Medical condition: Indication: Symptomatic Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064911 Pulmonary arterial hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000712-15 Sponsor Protocol Number: 001 Start Date*: 2018-12-17
    Sponsor Name:Andrew Lindford
    Full Title: Prospective Randomised Non-inferiority Nordic Frostbite Treatment Study comparing tPA and iloprost therapy
    Medical condition: frostbite; severe frostbite results in devastating injuries leading to significant morbidity from frequent distal extremity amputations
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000091-25 Sponsor Protocol Number: 2014GU001B Start Date*: 2014-09-01
    Sponsor Name:Royal Brompton and Harefield NHS Foundation Trust
    Full Title: A single-centre, placebo-controlled, double-blinded, randomized, cross-over study of Iloprost (Ventavis®) in patients with Eisenmenger syndrome
    Medical condition: Pulmonary Arterial Hypertension Eisenmenger syndrome
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004855 10037405 Pulmonary hypertension primary LLT
    17.0 100000004855 10037406 Pulmonary hypertension secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001325-34 Sponsor Protocol Number: 17/2008/U/Sper Start Date*: 2008-04-01
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: PROMISE AMI (PROtection of coronary Microcirculation by Iloprost: Safety and Efficacy evaluation in Acute Myocardial Infarction treated by primary PCI) Pilot Study
    Medical condition: Acute myocardial infarction
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064346 STEMI LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-003813-24 Sponsor Protocol Number: SIFU17 Start Date*: 2019-11-28
    Sponsor Name:Charité-Universitätsmedizin Berlin
    Full Title: A phase I/IIa, prospective, mono-center, randomized, open labeled, controlled study to assess the safety and efficacy of applying Iloprost locally in the fracture site to promote bone healing in pa...
    Medical condition: Proximal humeral fracture
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002712-28 Sponsor Protocol Number: DS/04/ENDO/01 Start Date*: 2005-02-28
    Sponsor Name:ITALFARMACO
    Full Title: Chronic iloprost administration in scleroderma patients effect on disease progression, as assessed by skin fibrosis evaluation. A randomized, controlled, blind-observer, multicenter phase III study.
    Medical condition: Disease progression in scleroderma.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10039711 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-001319-39 Sponsor Protocol Number: 18/2008/U/Sper Start Date*: 2008-04-11
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: PROtection of coronary Microcirculation by Iloprost: Safety and Efficacy in Percutaneous Coronary Intervention
    Medical condition: Coronary heart disease with stable angina or non-ST elevation myocardial infarction (NSTEMI)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051592 Acute coronary syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-002998-11 Sponsor Protocol Number: ENDO-RCA Start Date*: 2014-11-14
    Sponsor Name:Rigshospitalet, Capital Region Bloodbank 2034, Section for Transfusion Medicine
    Full Title: Safety and efficacy of low-dose Iloprost administration and blood pressure target in addition to standard therapy, as compared to standard therapy alone, in post-cardiac- arrest-syndrome patients...
    Medical condition: Cardiac Arrest
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004849 10007517 Cardiac arrest transient LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-002803-42 Sponsor Protocol Number: 15.05.2007 Start Date*: 2008-03-05
    Sponsor Name:Univ.Clinic of Internal Medicine II, Department of Cardiology, Medical University of Vienna, Austria
    Full Title: Inhaled Iloprost for patients with pulmonary arterial hypertension and right heart failure:a pilot feasibility trial
    Medical condition: Pulmonary arterial hypertension (PAH) is associated with poor prognosis.The most common cause of death is right heart failure. The fact that right heart failure is associated with low systemic per...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002726-32 Sponsor Protocol Number: 65/2006/U/Sper Start Date*: 2006-06-20
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: PROtection of coronary Microcirculation by Iloprost: Safety and Efficacy evaluation in PCI
    Medical condition: coronary angioplasty
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050329 Coronary angioplasty LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001613-33 Sponsor Protocol Number: BRIDGE Start Date*: 2014-05-13
    Sponsor Name:Thoraxclinic at the University of Heidelberg
    Full Title: Iloprost for Bridging to Heart Transplantation in Patients with Pulmonary Hypertension and Left Heart Failure
    Medical condition: Pulmonary Hypertension and Left Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004849 10024106 Left heart failure LLT
    16.1 100000004855 10037406 Pulmonary hypertension secondary LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000624-20 Sponsor Protocol Number: ILONA Start Date*: 2021-06-17
    Sponsor Name:Leipzig University
    Full Title: Core decompression versus core decompression followed by infusion of Iloprost in the treatment of non-traumatic avascular necrosis of the femoral head
    Medical condition: non-traumatic avascular necrosis of the femoral head (N-ANFH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10003860 Avascular necrosis femoral head LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003310-17 Sponsor Protocol Number: AC-063B201 Start Date*: 2011-11-23
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: "Estudio fase II, multicentrico, doble ciego, randomizado, controlado con placebo para evaluar los efectos de IIoprost inhalado en una prueba de resistencia durante un test de ejercicio cardiopulmo...
    Medical condition: Hipertension pulmonar secundaria a enfermedad obstructiva pulmonar cronica Pulmonary Hypertension Secondary to Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037406 Pulmonary hypertension secondary LLT
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 13 15:03:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA